Carmen Chang

Carmen Chang has an estimated net worth of $402 Million. This is based on reported shares across multiple companies, which include Marker Therapeutics, Inc., NeueHealth, Inc., Monte Rosa Therapeutics, Inc., Mirum Pharmaceuticals, Inc., Coursera, Inc., GENOCEA BIOSCIENCES, INC., Metacrine, Inc., Savara Inc, Trevi Therapeutics, Inc., Akouos, Inc., Black Diamond Therapeutics, Inc., Arsanis, Inc., Regulus Therapeutics Inc., Korro Bio, Inc., MBX Biosciences, Inc., and SpyGlass Pharma, Inc..

2021 was Carmen Chang's most active year for acquiring shares with 16 total transactions. Carmen Chang's most active month to acquire stocks was the month of September. 2025 was Carmen Chang's most active year for disposing of shares, totalling 22 transactions. Carmen Chang's most active month to dispose stocks was the month of September. 2022 saw Carmen Chang paying a total of $350,199,999.40 for 6,926,881 shares, this is the most they've acquired in one year. In 2022 Carmen Chang cashed out on 14,671,143 shares for a total of $750,662.12, their largest year based on trade value.